Q3 2025

Diagnosis and Management of Group 2 Pulmonary Hypertension Due to Left Heart Disease in the UAE

Hani Sabbour · Mohammed B Al Saiari · Ashraf Alzaabi · Hazem El Badaoui · Rizwan Ahmed · Hadi Skouri · Mohammad Daud Khan · Mohamed El Harari · Magdi Tofeig · Amrish Agrawal · Hosam Zaky · Noha Yaseen · Wael Al Mahmeed · Ahmed Reda Taha · Vivek Kakar · Yasser El Hennawi · Yogeeswari Vellore Satyanarayanan · Aref Al Hakami · Anwar Al Zaabi · Hussein Heshmat · Asim A. Alnour · Abdullah Shehab · Adbha Saleh Al Mubarak
10.2174/0102506882333546250115060157 388 المشاهدات 0 الاقتباسات
0
الاقتباسات
388
المشاهدات
الملخص


:
Pulmonary hypertension (PH) due to left heart disease (PH-LHD) is the most common type of PH and is observed in patients with underlying left heart disease conditions, including valvular heart disease, heart failure (HF) with preserved ejection fraction (HFpEF), HF with reduced ejection fraction (HFrEF), cardiomyopathies, and arrhythmic diseases. Group 2 PH is postcapillary PH categorised into 2 components as isolated postcapillary PH (IpcPH) and combined precapillary and postcapillary PH (CpcPH), based on the value of pulmonary vascular resistance (PVR).


:
PH-LHD diagnosis is a three-step process and includes identification of clinical phenotype, determination of pre-test probability for invasive evaluation, and haemodynamic assessments. Management of PH-LHD primarily encompasses optimisation of treatment of underlying conditions, such as hypertension, obesity and diabetes mellitus, and treatment of PH-LHD with targeted PAH-specific drugs, like phosphodiesterase type 5 inhibitors (PDE5i) and sildenafil. In patients with PH-LHD, the use of PAH-specific drugs can lead to pulmonary oedema and clinical deterioration.


:
The article aimed to provide updated information on diagnosis and emerging treatment options for PH-LHD. Although the emerging alternative treatment options are not approved, the randomised studies discussed provide insight into the management and thus demand future clinical trials to establish the safety and efficacy of novel molecules and combination therapies.

الاستشهاد بهذا المقال (APA)
Hani, S., Mohammed, B. A. S., Ashraf, A., Hazem, E. B., Rizwan, A., Hadi, S., Mohammad, D. K., Mohamed, E. H., Magdi, T., Amrish, A., Hosam, Z., Noha, Y., Wael, A. M., Ahmed, R. T., Vivek, K., Yasser, E. H., Yogeeswari, V. S., Aref, A. H., Anwar, A. Z., Hussein, H., Asim, A. A., Abdullah, S., Adbha, S. A. M. (2025). Diagnosis and Management of Group 2 Pulmonary Hypertension Due to Left Heart Disease in the UAE. New Emirates Medical Journal. https://doi.org/10.2174/0102506882333546250115060157
أبحاث ذات صلة
Anabolic Androgenic Steroids: A Review
Siya Rohilla; Prerna Sharma; Sweta Kamboj; Sanchit Dhankhar; Nitika Garg; Samrat · 2024
11
استشهاد
386
Caveolae’s Behavior in Norm and Pathology
Basheer Abdullah Marzoog · 2023
10
استشهاد
392
A Comprehensive Review of Alternative Therapeutic Approaches for Nausea and Vomiting Relief in Pregn…
Manish Panchal; Priyakshi Rana; Nitika Garg; Sanchit Dhankhar; Himanshu Sharma; · 2024
10
استشهاد
387
Prevalence and Impact of Dysmenorrhea on the Academic Performance of Students at Medical and Health …
Nayesha Mahwish; Rajani Dube; Subhranshu Sekhar Kar; Malavika Santhosh; Alweena · 2024
8
استشهاد
392
الوصول
عرض النص الكامل عبر DOI
نُشر في
الرقم الدولي ISSN 0250-6882
الربعية Q3
درجة المؤشر القياس العربي 57
التخصص Medicine & Health Sciences
الناشر Bentham Science Publishers Ltd.
الدولة 🇦🇪 UAE
عرض ملف المجلة →
المؤلفون
تفاصيل النشر
السنة 2025
اللغة English
أُضيف في 30 Jul 2026